PMID- 31259216
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231011
IS  - 2347-5625 (Print)
IS  - 2349-6673 (Electronic)
IS  - 2347-5625 (Linking)
VI  - 6
IP  - 3
DP  - 2019 Jul-Sep
TI  - Adverse Events of Oncologic Immunotherapy and Their Management.
PG  - 212-226
LID - 10.4103/apjon.apjon_6_19 [doi]
AB  - Over the past two decades, immunotherapy has emerged as a promising treatment 
      option for patients with cancer. However, newer versions of immunotherapy, such 
      as checkpoint inhibitors, may be associated with unusual adverse effects (AEs) 
      that can range in severity from mild to life-threatening. Unlike common AEs of 
      conventional chemotherapy, which have a predictable nadir or cyclic pattern after 
      administration, AEs of these newer immunotherapies are variable, depending on the 
      type of immunotherapy, route of administration, and mechanism of action. The 
      onset and resolution of these AEs may be present at any time, during 
      administration of treatment, a few weeks after administration of treatment, or 
      several months after completion of treatment. Therefore, improving outcomes in 
      patients undergoing oncologic immunotherapy requires oncology nurses' knowledge 
      and understanding of various immunotherapy agents, as well as early recognition 
      and management of potential AEs, especially AEs associated with checkpoint 
      inhibitors and other therapies that manipulate T-cell activation causing 
      autoimmune toxicity. This article draws upon current evidence from systematic 
      reviews, meta-analyses, and expert consensus guidelines to provide a brief 
      overview of common immunotherapies used in cancer and management of their 
      associated AEs.
FAU - Barber, Fedricker Diane
AU  - Barber FD
AD  - Department of Investigational Cancer Therapeutics (A Phase I Program), University 
      of Texas MD Anderson Cancer Center, Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Asia Pac J Oncol Nurs
JT  - Asia-Pacific journal of oncology nursing
JID - 101673157
PMC - PMC6518984
OTO - NOTNLM
OT  - Adverse events
OT  - cancer
OT  - immunotherapy
OT  - management
COIS- There are no conflicts of interest.
EDAT- 2019/07/02 06:00
MHDA- 2019/07/02 06:01
PMCR- 2019/07/01
CRDT- 2019/07/02 06:00
PHST- 2019/07/02 06:00 [entrez]
PHST- 2019/07/02 06:00 [pubmed]
PHST- 2019/07/02 06:01 [medline]
PHST- 2019/07/01 00:00 [pmc-release]
AID - S2347-5625(21)00256-0 [pii]
AID - APJON-6-212 [pii]
AID - 10.4103/apjon.apjon_6_19 [doi]
PST - ppublish
SO  - Asia Pac J Oncol Nurs. 2019 Jul-Sep;6(3):212-226. doi: 10.4103/apjon.apjon_6_19.